• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Surgical operation in hemophilia B. Use of factor IX concentrate.乙型血友病的外科手术。IX因子浓缩物的应用。
Calif Med. 1970 Jul;113(1):4-8.
2
Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.热处理的新西兰凝血因子IX浓缩剂：与乙型血友病患者使用的凝血酶原复合物的比较。
N Z Med J. 1986 Jun 11;99(803):408-9.
3
Treatment of hemophilia B with a new clotting-factor concentrate.用一种新型凝血因子浓缩物治疗乙型血友病。
N Engl J Med. 1969 Mar 13;280(11):581-6. doi: 10.1056/NEJM196903132801103.
4
Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.血友病B患者输注单克隆抗体纯化的凝血因子IX浓缩物后体内凝血因子IX恢复情况的变异性。单克隆凝血因子IX浓缩物（Mononine）研究组
Thromb Haemost. 1995 May;73(5):779-84.
5
Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.在手术期间及术后接受反复大剂量IX因子浓缩物治疗的B型血友病患者的高凝状态标志物。
Thromb Haemost. 1994 Jun;71(6):737-40.
6
Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.高纯度凝血因子 IX 浓缩物（Grifols 因子 IX）的药代动力学研究，对先前接受治疗的乙型严重血友病患者进行 6 个月随访。
Haemophilia. 2009 Nov;15(6):1243-8. doi: 10.1111/j.1365-2516.2009.02052.x. Epub 2009 Jul 30.
7
An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.一项评估高纯度因子 IX 浓缩物 Grifols 因子 IX 在严重乙型血友病患者中的疗效和安全性的开放性临床研究。
Haemophilia. 2010 Mar;16(2):240-6. doi: 10.1111/j.1365-2516.2009.02090.x. Epub 2009 Dec 14.
8
[Preparation and clinical use of a new factor IX concentrate].[一种新型凝血因子IX浓缩剂的制备及临床应用]
Acta Haematol Pol. 1978 Apr-Jun;9(2):107-12.
9
The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.用二乙氨基乙基纤维素制备凝血因子IX、II和X浓缩剂及其治疗效果。
Folia Haematol Int Mag Klin Morphol Blutforsch. 1975;102(5):591-4.
10
Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.通过放射免疫测定法检测因子IX抗原。华法林治疗患者及血友病B患者中的异常因子IX蛋白。
J Clin Invest. 1977 May;59(5):900-10. doi: 10.1172/JCI108712.

引用本文的文献

1
Current transfusion therapy.当前的输血治疗
Calif Med. 1973 May;118(5):38-55.

本文引用的文献

1
A simple, specific one-stage prothrombin assay using Russell's viper venom in cephalin suspension.一种在脑磷脂悬浮液中使用罗素蝰蛇毒的简单、特异的一步法凝血酶原测定法。
J Lab Clin Med. 1955 Jul;46(1):89-97.
2
THE IDENTIFICATION AND SYNTHESIS OF ACTIVATED PLASMA THROMBOPLASTIN COMPONENT (PTC').活性血浆凝血活酶成分（PTC'）的鉴定与合成
Blood. 1963 Dec;22:733-49.
3
Treatment of haemophilia B with purified Factor IX (PPSB).
Folia Med Neerl. 1967;10(4):112-25.
4
Treatment of hemophilia B with a new clotting-factor concentrate.用一种新型凝血因子浓缩物治疗乙型血友病。
N Engl J Med. 1969 Mar 13;280(11):581-6. doi: 10.1056/NEJM196903132801103.
5
Evaluation of a new concentrate for the treatment of factor IX deficiency.一种用于治疗IX因子缺乏症的新型浓缩剂的评估。
N Engl J Med. 1969 Feb 6;280(6):291-5. doi: 10.1056/NEJM196902062800603.

乙型血友病的外科手术。IX因子浓缩物的应用。

Surgical operation in hemophilia B. Use of factor IX concentrate.

作者信息

Kasper C K

出版信息

Calif Med. 1970 Jul;113(1):4-8.

PMID:5520728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1501202/
Abstract

A concentrate containing plasma clotting factors II, VII, IX and X was used to secure hemostasis for a herniorrhaphy, an osteotomy of a femur, a cup arthroplasty of a hip, and a tonsillectomy in patients with factor IX deficiency. After single infusions of concentrate, the net increase in plasma factor IX activity was 0.7 to 1.0 percent for each in-vitro unit of factor IX infused per kilogram of body weight. After large infusions of concentrate in two patients, the disappearance pattern of factor IX had two phases: a first component with half-disappearance times of 4.4 and 6 hours, and a second component with half-disappearance times of 26 and 32.6 hours.

摘要

一种含有血浆凝血因子II、VII、IX和X的浓缩物被用于为患有IX因子缺乏症的患者在疝修补术、股骨截骨术、髋关节杯形关节成形术和扁桃体切除术中实现止血。单次输注浓缩物后，每公斤体重输注1个体外单位的IX因子，血浆IX因子活性的净增加为0.7%至1.0%。在两名患者中大量输注浓缩物后，IX因子的消失模式有两个阶段：第一个成分的半衰期为4.4小时和6小时，第二个成分的半衰期为26小时和32.6小时。